02/27/2018 | Press release | Archived content

A phase 2 study of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in HER2 negative breast cancer patients with abnormal HER2 driven signaling transduction (NCT03412643)

Please select the service you want to use:

• Newsvine
• Digg
• Delicious
• StumbleUpon
• Technorati
• Buzz
• Favorites
• Google Reader

 Back

 Download the original document